Display options
Cite
Jacobson BA, Chen EZ, Tang S, et al. Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma. Genes Cancer. 2015;6(3):144-52doi: 10.18632/genesandcancer.55.
Jacobson, B. A., Chen, E. Z., Tang, S., Belgum, H. S., McCauley, J. A., Evenson, K. A., Etchison, R. G., Jay-Dixon, J., Patel, M. R., Raza, A., Saluja, A. K., D'Cunha, J., & Kratzke, R. A. (2015). Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma. Genes & cancer, 6(3), 144-52. https://doi.org/10.18632/genesandcancer.55
Jacobson, Blake A, et al. "Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma." Genes & cancer vol. 6,3 (2015): 144-52. doi: https://doi.org/10.18632/genesandcancer.55
Jacobson BA, Chen EZ, Tang S, Belgum HS, McCauley JA, Evenson KA, Etchison RG, Jay-Dixon J, Patel MR, Raza A, Saluja AK, D'Cunha J, Kratzke RA. Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma. Genes Cancer. 2015 Mar;6(3):144-52. doi: 10.18632/genesandcancer.55. PMID: 26000097; PMCID: PMC4426951.
Copy Download .nbib Format: NLM
Share it on

Genes Cancer. 2015 Mar;6(3):144-52. doi: 10.18632/genesandcancer.55.

Triptolide and its prodrug minnelide suppress Hsp70 and inhibit in vivo growth in a xenograft model of mesothelioma.

Genes & cancer

Blake A Jacobson, Esther Z Chen, Shaogeng Tang, Holly Sedgwick Belgum, Joel A McCauley, Kristen A Evenson, Ryan G Etchison, Joe Jay-Dixon, Manish R Patel, Ahmad Raza, Ashok K Saluja, Jonathan D'Cunha, Robert A Kratzke

Affiliations

  1. Departments of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  2. Departments of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.

PMID: 26000097 PMCID: PMC4426951 DOI: 10.18632/genesandcancer.55

Abstract

Malignant mesothelioma is a devastating disease with a poor prognosis for which there is a clear need for more successful therapeutic approaches. Triptolide, a diterpenoid triepoxide, is a highly effective agent against several cancer types in animal models. Owing to triptolide's poor solubility in water, a water-soluble analog, minnelide, was synthesized. Minnelide is a prodrug of triptolide and is activated by exposure to phosphatases that are found in all body tissues, including blood. Mesothelioma cells were treated in vitro with minnelide or its parent compound, triptolide. Minnelide and triptolide were both found to significantly reduce mesothelioma cell viability and induce apoptosis. The level of Hsp70, a protein that promotes cancer cell survival, was measured in mesothelioma cells before and after treatment with triptolide. Hsp70 levels were decreased in a dose-dependent manner. In addition, triptolide sensitized cells to gemcitabine and pemetrexed as measured by cell viability. Mice bearing mesothelioma flank tumors were treated with daily injections (28 d) of minnelide or saline solution and xenograft tumor growth recorded. Mice displayed significantly reduced tumor burden. These findings support the clinical evaluation of minnelide therapy for mesothelioma.

Keywords: Hsp70; Triptolide; mesothelioma; minnelide

References

  1. Oncogene. 2007 Oct 25;26(49):6959-67 - PubMed
  2. Clin Lung Cancer. 2009 Mar;10(2):112-7 - PubMed
  3. Anticancer Res. 2002 Mar-Apr;22(2A):665-72 - PubMed
  4. Semin Oncol. 2002 Feb;29(1):18-25 - PubMed
  5. Cancer Lett. 2012 Dec 28;325(2):117-24 - PubMed
  6. Surgery. 2009 Aug;146(2):282-90 - PubMed
  7. Carcinogenesis. 2013 Jun;34(6):1181-8 - PubMed
  8. Molecules. 2011 Jun 23;16(6):5283-97 - PubMed
  9. Clin Exp Pharmacol Physiol. 2012 Mar;39(3):311-20 - PubMed
  10. PLoS One. 2013 Oct 15;8(10):e77411 - PubMed
  11. Oncogene. 1999 Jun 17;18(24):3648-51 - PubMed
  12. Mol Cancer Ther. 2013 Jul;12(7):1266-75 - PubMed
  13. J Surg Res. 2010 Sep;163(1):72-8 - PubMed
  14. Biochem Biophys Res Commun. 1996 Jan 17;218(2):582-7 - PubMed
  15. J Biomed Biotechnol. 2009;2009:451084 - PubMed
  16. Oncogene. 2011 Jun 23;30(25):2836-45 - PubMed
  17. Genes Dev. 2005 Mar 1;19(5):570-82 - PubMed
  18. Sci Transl Med. 2012 Oct 17;4(156):156ra139 - PubMed
  19. Nat Chem Biol. 2011 Mar;7(3):182-8 - PubMed
  20. Proteomics. 2003 Oct;3(10 ):1904-11 - PubMed
  21. Mol Cancer Ther. 2009 Oct;8(10 ):2780-90 - PubMed
  22. Cancer Res. 2007 Oct 1;67(19):9407-16 - PubMed
  23. Int Immunopharmacol. 2011 Mar;11(3):377-83 - PubMed
  24. J Am Chem Soc. 1972 Oct 4;94(20):7194-5 - PubMed
  25. J Surg Res. 2010 Oct;163(2):244-9 - PubMed
  26. Cancer Lett. 2013 Jul 28;335(2):412-20 - PubMed
  27. J Clin Oncol. 2003 Jul 15;21(14):2636-44 - PubMed

Publication Types